JP2016519051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519051A5 JP2016519051A5 JP2015562159A JP2015562159A JP2016519051A5 JP 2016519051 A5 JP2016519051 A5 JP 2016519051A5 JP 2015562159 A JP2015562159 A JP 2015562159A JP 2015562159 A JP2015562159 A JP 2015562159A JP 2016519051 A5 JP2016519051 A5 JP 2016519051A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- pcsk9
- mutein
- tear lipocalin
- human tear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781511P | 2013-03-14 | 2013-03-14 | |
| US61/781,511 | 2013-03-14 | ||
| EP13175023.4 | 2013-07-04 | ||
| EP13175023 | 2013-07-04 | ||
| PCT/EP2014/055013 WO2014140210A1 (en) | 2013-03-14 | 2014-03-13 | Novel binding proteins for pcsk9 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519051A JP2016519051A (ja) | 2016-06-30 |
| JP2016519051A5 true JP2016519051A5 (enExample) | 2017-04-13 |
| JP6619650B2 JP6619650B2 (ja) | 2019-12-11 |
Family
ID=48703321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562159A Expired - Fee Related JP6619650B2 (ja) | 2013-03-14 | 2014-03-13 | 新規のｐｃｓｋ９結合タンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9150629B2 (enExample) |
| EP (1) | EP2968490A1 (enExample) |
| JP (1) | JP6619650B2 (enExample) |
| KR (1) | KR20150131151A (enExample) |
| CN (1) | CN105246503A (enExample) |
| AU (1) | AU2014230460B2 (enExample) |
| BR (1) | BR112015021681A2 (enExample) |
| CA (1) | CA2905186A1 (enExample) |
| HK (1) | HK1213194A1 (enExample) |
| IL (1) | IL241329A0 (enExample) |
| MX (1) | MX2015012420A (enExample) |
| PH (1) | PH12015501687A1 (enExample) |
| RU (1) | RU2015142437A (enExample) |
| SG (1) | SG11201505856TA (enExample) |
| WO (1) | WO2014140210A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP2968490A1 (en) | 2013-03-14 | 2016-01-20 | Daiichi Sankyo Co., Ltd. | Novel binding proteins for pcsk9 |
| WO2015095553A1 (en) * | 2013-12-20 | 2015-06-25 | Nephrogenesis, Llc | Methods and apparatus for kidney dialysis |
| US9398085B2 (en) | 2014-11-07 | 2016-07-19 | Ringcentral, Inc. | Systems and methods for initiating a peer-to-peer communication session |
| RU2736312C2 (ru) | 2015-05-04 | 2020-11-13 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Белки, специфичные в отношении cd137 |
| EP3793612A4 (en) | 2018-05-16 | 2022-03-02 | LIB Therapeutics, LLC | COMPOSITIONS CONTAINING PCSK9 BINDING MOLECULES AND METHODS OF USE |
| ES3015132T3 (en) | 2018-06-21 | 2025-04-29 | Ucb Holdings Inc | Cyclic polypeptides for pcsk9 inhibition |
| WO2019246386A1 (en) | 2018-06-21 | 2019-12-26 | Ra Pharmaceuticals Inc. | Cyclic polypeptides for pcsk9 inhibition |
| JOP20190150A1 (ar) * | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
| RS66416B1 (sr) | 2019-01-18 | 2025-02-28 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene |
| KR20210146999A (ko) | 2019-03-29 | 2021-12-06 | 피어이스 파마슈티컬즈 게엠베하 | 리포칼린 뮤테인의 흡입 투여 |
| EP4076492A4 (en) | 2019-12-20 | 2024-01-17 | Merck Sharp & Dohme LLC | PCSK9 ANTAGONIST COMPOUNDS |
| CN114981288B (zh) * | 2020-07-27 | 2024-05-03 | 深圳华大生命科学研究院 | 一种抗体结合的特征性表位及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| TR200003635T2 (tr) | 1998-06-08 | 2001-04-20 | F.Hoffmann-La Roche Ag | Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| AT411852B (de) | 2002-02-12 | 2004-06-25 | Didosyan Yuri S Dr | Verfahren und vorrichtung zur änderung des polarisationszustandes von licht mit einem magnetisch einachsigen kristall |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| EP1996613B1 (en) | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| CN104650213A (zh) | 2006-08-01 | 2015-05-27 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| WO2008057457A2 (en) * | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| EP2083861A4 (en) * | 2006-11-07 | 2010-11-24 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
| WO2008125623A2 (en) * | 2007-04-13 | 2008-10-23 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| AU2008281913B2 (en) | 2007-07-31 | 2013-11-07 | Affibody Ab | New albumin binding compositions, methods and uses |
| US8986951B2 (en) * | 2010-06-08 | 2015-03-24 | Pieris Ag | Tear lipocalin in muteins binding IL-4 R alpha |
| WO2012004384A2 (en) | 2010-07-09 | 2012-01-12 | Affibody Ab | Polypeptides |
| SG11201403887WA (en) * | 2012-01-09 | 2014-08-28 | Pieris Ag | Methods for preventing, treating or diagnosing disorders |
| EP2968490A1 (en) | 2013-03-14 | 2016-01-20 | Daiichi Sankyo Co., Ltd. | Novel binding proteins for pcsk9 |
-
2014
- 2014-03-13 EP EP14716250.7A patent/EP2968490A1/en not_active Withdrawn
- 2014-03-13 KR KR1020157028381A patent/KR20150131151A/ko not_active Ceased
- 2014-03-13 BR BR112015021681A patent/BR112015021681A2/pt not_active Application Discontinuation
- 2014-03-13 AU AU2014230460A patent/AU2014230460B2/en not_active Ceased
- 2014-03-13 US US14/208,629 patent/US9150629B2/en active Active
- 2014-03-13 WO PCT/EP2014/055013 patent/WO2014140210A1/en not_active Ceased
- 2014-03-13 RU RU2015142437A patent/RU2015142437A/ru not_active Application Discontinuation
- 2014-03-13 SG SG11201505856TA patent/SG11201505856TA/en unknown
- 2014-03-13 HK HK16101229.3A patent/HK1213194A1/zh unknown
- 2014-03-13 JP JP2015562159A patent/JP6619650B2/ja not_active Expired - Fee Related
- 2014-03-13 MX MX2015012420A patent/MX2015012420A/es unknown
- 2014-03-13 CA CA2905186A patent/CA2905186A1/en not_active Abandoned
- 2014-03-13 CN CN201480012827.2A patent/CN105246503A/zh active Pending
-
2015
- 2015-07-30 PH PH12015501687A patent/PH12015501687A1/en unknown
- 2015-08-28 US US14/839,222 patent/US9598476B2/en not_active Expired - Fee Related
- 2015-09-08 IL IL241329A patent/IL241329A0/en unknown
-
2017
- 2017-02-28 US US15/445,066 patent/US20170173112A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519051A5 (enExample) | ||
| RU2015142437A (ru) | Новые связывающие белки для pcsk9 | |
| EP3015477B1 (en) | High-stability t-cell receptor and preparation method and application thereof | |
| JP2018532372A5 (enExample) | ||
| Iyengar et al. | The complete amino‐acid sequence of the sweet protein thaumatin I | |
| JP2018526989A5 (enExample) | ||
| JP2018519802A5 (enExample) | ||
| JP2013537400A5 (enExample) | ||
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| RU2012150766A (ru) | Мутеины липокалина слезы, связывающие альфа il-4 r | |
| JP2018519803A5 (enExample) | ||
| JP2018515085A5 (enExample) | ||
| JP2018515084A5 (enExample) | ||
| RU2015137158A (ru) | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ | |
| JP2012531212A5 (enExample) | ||
| JP2019506140A5 (enExample) | ||
| JP2016505826A5 (enExample) | ||
| JPH06508742A (ja) | 組換えトロンビンレセプターおよびそれに関連した薬剤 | |
| JP2014500724A5 (enExample) | ||
| WO2008122434A8 (en) | Bis-met histones | |
| RU2017135605A (ru) | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) | |
| CN108025059B (zh) | 抗猫过敏的组合物 | |
| AU2020200990A1 (en) | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies | |
| EP3299389A1 (en) | Soluble and stable heterodimeric tcr | |
| JP2020505948A5 (enExample) |